How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper – Neumann – – British Journal of Clinical Pharmacology – Wiley Online Library The safety and efficacy of pharmacotherapy in children, particularly preterms, neonates and infants, is limited by a paucity of good-quality data from prospective clinical drug trials.…
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper by Aurich et al British Journal of Clinical Pharmacology – Wiley Online Library Children frequently respond differently to therapies compared to adults. Differences also exist between Paediatric age groups for pharmacokinetics and pharmacodynamics in both…
Meet the team behind c4c! We are a diverse group of people from many different backgrounds, but all of us are working towards a common goal: better medicines for children through European clinical trials. Today’s spotlight is on Lionel Tan, one of the industry representatives helping to steer the direction of c4c. Lionel Tan…
How Can a Clinical Data Modelling Tool Be Used to Represent Data Items of Relevance to Paediatric Clinical Trials? Learning from the Conect4children (c4c) Consortium The c4c have published a new article on the Direcht clinical data modelling tool in Applied Sciences. “c4c is piloting the Direcht clinical data modelling tool to model their Cross Cutting…
c4c have published ‘Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project” in British Journal of Clinical Pharmacology. “The medicine development process is complex and requires time and effort to ensure safety, efficacy and quality. In paediatrics, this process is even more challenging, as it involves a subgroup of…
Back in November 2016, the first meeting for the constitution of RECLIP was held at La Paz Research Institute in Madrid (IdiPAZ). By that time, the network consisted of 12 reference hospitals, the Foundation for the Promotion of Health and Biomedical Research (FISABIO) and 2 research networks RITIP (Translational Research Network in Pediatric Infectious Diseases)…
Do you know that only about 30% of medicines in Europe and worldwide are authorized for use in paediatrics and that less than 50% of medicines commonly used in children have been properly evaluated in this population? This rate drops to 10% in the vulnerable patient population in neonatal intensive care. The current consensus is…
Maria Cavaller (Patient Engagement Manager) and Gulcin Gumus (Research and Policy Project Manager) are from patient organisation EURORDIS-Rare Diseases Europe, which is a c4c project partner. We talked to them about how patient organizations can take part in the c4c project, the importance of engaging young patients in research and having patients as equal partners…
c4c is a success. During 2021 c4c actions have influenced other organizations and shown why c4c is important. Despite many difficulties, c4c is very effective because of the dedication by everyone who works on c4c. The hard work and dedication are paying off as we follow the c4c vision and mission. The impacts made by…
1 – 2 March 2022 – 4:00PM – 7:30PM CET (both days) – Virtual event Call for Expression of Interest (deadline: 14 January 2022) conect4children is pleased to announce that the second c4c International Multi-Stakeholder Meeting (MSM) will address paediatric Atopic Dermatitis (AD) and will take place VIRTUALLY on 1-2 MARCH 2022. The meeting is…
